Alzinova AB (publ) (STO:ALZ)

Sweden flag Sweden · Delayed Price · Currency is SEK
0.450
+0.006 (1.35%)
Apr 28, 2026, 5:29 PM CET
-76.09%
Market Cap 69.73M
Revenue (ttm) 26.80M
Net Income (ttm) -26.27M
Shares Out 154.96M
EPS (ttm) -0.27
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 307,783
Average Volume 943,683
Open 0.445
Previous Close 0.444
Day's Range 0.431 - 0.469
52-Week Range 0.436 - 2.280
Beta 1.15
RSI 27.29
Earnings Date Apr 23, 2026

About Alzinova AB

Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer’s disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer’s disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aβ42, called oligomers, which are considered to be the underlying cause of Alzheimer’s disease; and a humanized version of ALZ-201 in patients with Alzheimer’s d... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2011
Employees 5
Stock Exchange Nasdaq Stockholm
Ticker Symbol ALZ
Full Company Profile

Financial Performance

In 2025, Alzinova AB's revenue was 26.80 million, an increase of 59.44% compared to the previous year's 16.81 million. Losses were -26.27 million, 27.8% more than in 2024.

Financial Statements

News

Alzinova AB Transcript: Investing in Life Science 2025

Alzheimer's disease is a growing global challenge, and a new vaccine candidate aims to offer a cost-effective, safe, and convenient alternative to current treatments. Early clinical data show promising safety and efficacy, with a Phase 2 trial and regulatory milestones underway.

7 months ago - Transcripts